What is FoRx Therapeutics?
FoRx Therapeutics is a specialized, privately held clinical-stage biotechnology firm dedicated to the discovery and development of precision therapeutics. The company is primarily focused on targeting the DNA Damage Response (DDR) pathway, a critical area of research for overcoming treatment resistance in various oncology indications. Its lead product candidate, FORX-428, represents a significant advancement in the field as an oral small molecule PARG inhibitor. Currently undergoing Phase 1 clinical testing, the candidate is being evaluated for its efficacy in treating advanced solid tumors, positioning the company at the forefront of next-generation cancer therapy development.
How much funding has FoRx Therapeutics raised?
FoRx Therapeutics has raised a total of $60.8M across 2 funding rounds:
Seed
$10.8M
Series A
$50M
Seed (2020): $10.8M with participation from Novartis Venture Fund and Omega funds
Series A (2025): $50M led by Novartis Venture Fund, Pfizer, Merck Ventures, and EQT
Key Investors in FoRx Therapeutics
Novartis Venture Fund
The Novartis Venture Fund invests in innovative life science companies focused on biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Pfizer
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes.
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing in innovative technologies and products with the potential to significantly impact core business areas.
What's next for FoRx Therapeutics?
With the successful closure of this major enterprise-level funding, FoRx Therapeutics is set to prioritize the advancement of its clinical pipeline. The strategic allocation of these resources will likely focus on the expansion of Phase 1 trials for FORX-428, ensuring that the company maintains its momentum in the competitive landscape of precision medicine. Furthermore, the involvement of high-caliber institutional backers suggests a long-term commitment to scaling the company's operational capabilities and potentially exploring additional therapeutic targets within the DDR pathway. As the firm moves deeper into clinical development, the focus will shift toward generating robust data sets that validate the therapeutic potential of its PARG inhibitor technology, ultimately aiming to provide transformative outcomes for patients facing limited treatment options.
See full FoRx Therapeutics company page
